Next Article in Journal
Reproductive Potential of Yeast Cells Depends on Overall Action of Interconnected Changes in Central Carbon Metabolism, Cellular Biosynthetic Capacity, and Proteostasis
Next Article in Special Issue
The Interplay between Fe3O4 Superparamagnetic Nanoparticles, Sodium Butyrate, and Folic Acid for Intracellular Transport
Previous Article in Journal
Susceptibility Factors in Chronic Lung Inflammatory Responses to Engineered Nanomaterials
Previous Article in Special Issue
Injectable Thermo-Sensitive Chitosan Hydrogel Containing CPT-11-Loaded EGFR-Targeted Graphene Oxide and SLP2 shRNA for Localized Drug/Gene Delivery in Glioblastoma Therapy

Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery

Institute of Materials and Environmental Chemistry, Research Centre for Natural Sciences, Magyar tudósok körútja 2, H-1117 Budapest, Hungary
Research Institute of Biomolecular and Chemical Engineering, Faculty of Engineering, University of Pannonia, Egyetem u. 10, H-8200 Veszprém, Hungary
Centre of Polymer and Carbon Materials Polish Academy of Sciences, 34, M. Curie-Skłodowskiej Str., 41-819 Zabrze, Poland
Department of Microbiology and Virology School of Pharmacy with the Division of Laboratory Medicine Medical University of Silesia, 4 Jagiellońska St., 41-200 Sosnowiec, Poland
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(19), 7312;
Received: 2 September 2020 / Revised: 29 September 2020 / Accepted: 1 October 2020 / Published: 3 October 2020
Dual drug-loaded nanotherapeutics can play an important role against the drug resistance and side effects of the single drugs. Doxorubicin and sorafenib were efficiently co-encapsulated by tailor-made poly([R,S]-3-hydroxybutyrate) (PHB) using an emulsion–solvent evaporation method. Subsequent poly(ethylene glycol) (PEG) conjugation onto nanoparticles was applied to make the nanocarriers stealth and to improve their drug release characteristics. Monodisperse PHB–sorafenib–doxorubicin nanoparticles had an average size of 199.3 nm, which was increased to 250.5 nm after PEGylation. The nanoparticle yield and encapsulation efficiencies of drugs decreased slightly in consequence of PEG conjugation. The drug release of the doxorubicin was beneficial, since it was liberated faster in a tumor-specific acidic environment than in blood plasma. The PEG attachment decelerated the release of both the doxorubicin and the sorafenib, however, the release of the latter drug remained still significantly faster with increased initial burst compared to doxorubicin. Nevertheless, the PEG–PHB copolymer showed more beneficial drug release kinetics in vitro in comparison with our recently developed PEGylated poly(lactic-co-glycolic acid) nanoparticles loaded with the same drugs. View Full-Text
Keywords: poly(3-hydroxybutyrate); sorafenib; doxorubicin; dual drug-loaded nanoparticles poly(3-hydroxybutyrate); sorafenib; doxorubicin; dual drug-loaded nanoparticles
Show Figures

Figure 1

MDPI and ACS Style

Babos, G.; Rydz, J.; Kawalec, M.; Klim, M.; Fodor-Kardos, A.; Trif, L.; Feczkó, T. Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery. Int. J. Mol. Sci. 2020, 21, 7312.

AMA Style

Babos G, Rydz J, Kawalec M, Klim M, Fodor-Kardos A, Trif L, Feczkó T. Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery. International Journal of Molecular Sciences. 2020; 21(19):7312.

Chicago/Turabian Style

Babos, György, Joanna Rydz, Michal Kawalec, Magdalena Klim, Andrea Fodor-Kardos, László Trif, and Tivadar Feczkó. 2020. "Poly(3-Hydroxybutyrate)-Based Nanoparticles for Sorafenib and Doxorubicin Anticancer Drug Delivery" International Journal of Molecular Sciences 21, no. 19: 7312.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop